The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting

Discover More

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma

August 4, 2021

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

June 9, 2021

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

December 1, 2020

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

RTNova

Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies

American Association for Cancer Research

August 15, 2020

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

RTNova

Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects

American Association for Cancer Research

August 15, 2020

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner, Personalized Stem Cells

August 3, 2020

Press Release

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company, announced a $2 million registered direct offering and concurrent private placement involving the sale of 2,050,000 shares of common stock and warrants for additional shares

October 23, 2024

Discover More

Press Release

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared Northwestern University’s Investigational New Drug (IND) application for Calidi’s CLD-101. CLD-101 is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors, enhancing their antitumor effects. The Phase 1b/2 clinical trial is expected to commence in late 2024 at Northwestern University.

September 30, 2024

Discover More

Press Release

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024...

August 13, 2024

Discover More

Press Release

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor...

July 29, 2024

Discover More

Press Release

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi Biotherapeutics announced a new patent for its SuperNova technology, advancing its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccine. This strengthens Calidi’s position in developing innovative therapies for advanced solid tumors.

July 18, 2024

Discover More

Press Release

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi

July 16, 2024

Discover More

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

November 7, 2018

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapies

November 7, 2018

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

November 7, 2018

Media

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

February 3, 2024

Discover More

Media

Big Biz TV - Allan Camaisa

Pioneering Progress: Calidi Biotherapeutics CEO Allan Camaisa Unveils Latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023

Discover More

Media

Big Biz TV - Stephen Thesing

Pioneering Progress: Calidi Biotherapeutics CBO Stephen Thesing discusses the latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023

Discover More

In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023

Discover More

In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023

Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more

The Newsroom

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies

Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects

Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner, Personalized Stem Cells

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

Big Biz TV - Allan Camaisa

Big Biz TV - Stephen Thesing

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.